1. South Korea Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
i-SENS Inc

i-SENS Inc

099190.KS
i-SENS IncKR flagKorea Exchange
21,000.00
KRW
-150.00
- -
603.88BMarket Cap
i-SENS Inc
099190.KS
(Korea Exchange)

Recent

price

21,000.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
2,759.98
3,090.73
3,513.83
3,729.59
4,827.75
5,717.58
6,313.59
6,981.63
7,491.44
8,566.89
4,824.76
9,649.67
10,548.16
11,456.43
11,324.7
Revenue per Share
362.67
695.33
531.67
538.5
640
573
825.5
861.5
987
936.04
294
135
-65
-187
-208.79
Basic EPS, GAAP
-450.02
-474.2
351.77
322.47
114.22
-66.82
328.69
1,115.44
978.64
-1,139
-302.68
-1,077.48
267.33
-302.83
-508.8
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
49.98
50.12
74.99
99.99
125
74.3
174.93
99.67
100.38
- -
Dividend per Share
1,592.31
2,101.19
2,569.73
3,149.28
3,793.5
4,312.94
4,914
5,726.48
6,755.49
7,553.97
4,022.84
8,201.63
8,043.68
7,722.84
7,649.35
Book Value per Share
2,754.79
3,752.19
4,236.52
4,777.04
4,771.36
5,312.12
5,956.17
6,806.61
7,688.09
9,953.29
5,279.05
9,646.23
11,249.57
11,097.12
11,619.59
Tangible Book Value per Share
24
27
27
27
27
27
27
27
27
27
55
27
28
28
28
Basic Weighted Avg Shares
66,549
82,863
95,608
101,921
132,468
156,964
172,997
189,844
203,708
232,935
264,837
265,120
291,138
315,445
314,305
Sales/Revenue/Turnover
11.93
22.39
18.96
19.05
19.4
14.5
15.84
15.89
14.95
14.95
7.48
4.12
0.91
2.5
1.78
Operating Margin (%)
5,251
6,289
6,919
7,585
5,830
7,253
7,550
10,016
10,918
10,894
12,054
13,566
15,918
17,194
17,507
Depreciation Expense
8,745
18,642
14,466
14,716
17,561
15,730
22,619
23,426
26,839
25,451
16,138
3,709
-1,794
-5,149
-5,795
Net Income, GAAP
14.91
16.94
15.78
23.67
22.56
22.24
15.07
21.42
21.89
18.18
16.95
44.49
218.17
- -
177.94
Effective Tax Rate (%)
13.14
22.5
15.13
14.44
13.26
10.02
13.07
12.34
13.18
10.93
6.09
1.4
-0.62
-1.63
-1.84
Profit Margin (%)
24,056
47,590
63,351
59,297
62,702
69,999
82,551
87,191
128,317
169,263
142,624
78,466
163,494
91,469
111,790
Working Capital
9,003
21,420
27,935
25,319
23,007
37,876
34,420
20,599
44,608
95,239
66,061
48,656
113,850
62,717
71,331
LT Debt
68,437
104,319
118,808
132,222
152,231
165,152
183,267
201,091
223,126
284,740
304,756
303,495
342,981
338,321
356,487
Total Equity
- -
14.43
10.95
9.54
11.32
8.91
10.75
10.15
9.17
8.55
4.12
1.42
-0.65
- -
- -
Return on Invested Capital (%)
- -
28.38
16.85
14.51
14.2
11.34
14.14
13.37
12.58
9.44
5.4
1.56
-2.43
- -
4.26
Return on Capital (%)
- -
39.36
22.92
18.87
18.47
14.14
17.88
16.14
15.81
13.08
7.57
1.66
-0.8
-2.37
-2.67
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
99,654
111,081
99,234
LT Borrowings
72,315
61,518
70,235
LT Finance Leases
1,384
1,200
1,095
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
28
29
29
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
254,039
258,382
264,267
Cash, Cash Equivalents & STI
92,128
98,187
99,021
Accounts Receivable, Net
67,079
67,323
67,884
Inventories
76,516
74,480
80,547
Total Current Liabilities
149,308
166,913
152,477
Payables & Accruals
- -
- -
- -
ST Debt
99,654
111,081
99,234
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
10.12%
9.18%
-1.36%
Free Cash Flow
-111.18%
-104.5%
-213.01%
Net Income, GAAP
-0.93%
-16.03%
187%
Sales/Revenue/Turnover
12.2%
9.26%
8.35%
Total Cash Common Dividend
- -
4.11%
0.47%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
68,404
69,900
71,519
81,314
291,138
2025
76,269
76,789
78,727
83,659
315,445
2026
75,130
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-10
-0.1
31
- -
-65
2025
94
31.45
-14.34
- -
-187
2026
69.76
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
99.67
2025
- -
- -
- -
- -
100.38
2026
- -
- -
- -
- -
- -
Similar Companies
Paxman AB (publ) (PAX.ST)
Inspiration Healthcare Group plc (IHC.L)
Envoy Medical, Inc. (COCH)
Nanomix Corporation (NNMX)
QHSLab, Inc. (USAQ)
Bionovate Technologies Corp (BIIO)
Business
i-SENS, Inc. (099190.KS) develops, manufactures and markets in vitro diagnostic devices with a focus on blood glucose monitoring systems, continuous glucose monitoring systems, point-of-care testing analyzers and veterinary diagnostics; its core products include the CareSens series of blood glucose meters such as CareSens N, CareSens N Voice, CareSens N Premier, CareSens N Eco, CareSens PRO, CareSens H Beat, NoCoding1 Plus, KetoSens and CareSens S Fit; continuous glucose monitoring solutions led by CareSens Air and its app Sens365; point-of-care systems encompassing i-Smart blood gas analyzers, electrolyte analyzers, HbA1c analyzers like A1Care, immunoassay analyzers such as iVISEN IA-1100 and PT/INR analyzers; and veterinary care systems including i-Smart 30 VET. The Korea-based company, founded in 2000 and headquartered in Seoul's Seocho District, operates manufacturing facilities in Korea and China with an annual production capacity of 2.1 billion test strips, exporting to over 110 countries across North America, Europe, Asia and Latin America through subsidiaries including i-SENS USA Inc., i-SENS GmbH, i-SENS (Jiangsu) Co. Ltd., i-SENS Mexico S.A. de C.V., i-SENS Biosensors India Pvt. Ltd. and i-SENS Biosensors Malaysia Sdn. Bhd. Recent developments feature the September 2023 launch of CareSens Air, Korea's first domestically developed continuous glucose monitoring system certified for CE marking and rolled out in 14 countries in 2024 with expansion to over 30 markets by year-end alongside the November 2025 global debut of the CareSens Air Receiver; acquisition of AgaMatrix Inc. in July 2023 and CoaguSense Inc. in 2016; completion of the Incheon Songdo Plant 2 in October 2023 boosting CGM production to two million units annually; April 2024 convertible bond issuance acquired by ANDA Asset Management, Atinum Investment and Korea Investment Partners; and the March 2025 release of an upgraded CareSens Air CGM version.